S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

MariMed Stock Forecast, Price & News

-0.03 (-3.95%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
572,584 shs
Average Volume
1.16 million shs
Market Capitalization
$243.20 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

MariMed logo

About MariMed

MariMed, Inc. engages in direct owning of cannabis licenses and management of seed-to-sale operations. It focuses on the development, operation, management, and optimization of facilities for the cultivation, production, and dispensing of medicinal and recreational cannabis and cannabis-infused products. The company was founded by Robert N. Fireman and Jon Levine on January 25, 2011 and is headquartered in Norwood, MA.


MariMed (OTCMKTS:MRMD) Releases Earnings Results
November 16, 2021 |  americanbankingnews.com
MariMed Reports Third Quarter 2021 Earnings
November 15, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Data Processing, Hosting, and Related Services
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Market Cap
$243.20 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

1.87 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

MariMed (OTCMKTS:MRMD) Frequently Asked Questions

Is MariMed a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MariMed in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MariMed stock.
View analyst ratings for MariMed
or view top-rated stocks.

How has MariMed's stock been impacted by COVID-19 (Coronavirus)?

MariMed's stock was trading at $0.1599 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRMD shares have increased by 356.5% and is now trading at $0.73.
View which stocks have been most impacted by COVID-19

Are investors shorting MariMed?

MariMed saw a increase in short interest in October. As of October 15th, there was short interest totaling 308,000 shares, an increase of 26.7% from the September 30th total of 243,000 shares. Based on an average daily volume of 815,900 shares, the days-to-cover ratio is currently 0.4 days.
View MariMed's Short Interest

How were MariMed's earnings last quarter?

MariMed Inc. (OTCMKTS:MRMD) issued its earnings results on Monday, November, 15th. The company reported $0.01 EPS for the quarter.
View MariMed's earnings history

What guidance has MariMed issued on next quarter's earnings?

MariMed issued an update on its FY 2021 earnings guidance on Monday, November, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $118 million-$118 million, compared to the consensus revenue estimate of $118.50 million.

What price target have analysts set for MRMD?

1 brokers have issued 1-year price targets for MariMed's stock. Their forecasts range from $2.25 to $2.25. On average, they anticipate MariMed's share price to reach $2.25 in the next year. This suggests a possible upside of 208.2% from the stock's current price.
View analysts' price targets for MariMed
or view top-rated stocks among Wall Street analysts.

Who are MariMed's key executives?

MariMed's management team includes the following people:
  • Robert N. Fireman, Chairman, President & Chief Executive Officer
  • Timothy Shaw, Chief Operating Officer
  • Jon R. Levine, CFO, Secretary, Treasurer & Director
  • Ryan Crandall, Chief Product Officer & Senior VP-Sales
  • Steve West, Vice President-Investor Relations

Who are some of MariMed's key competitors?

What other stocks do shareholders of MariMed own?

What is MariMed's stock symbol?

MariMed trades on the OTCMKTS under the ticker symbol "MRMD."

How do I buy shares of MariMed?

Shares of MRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MariMed's stock price today?

One share of MRMD stock can currently be purchased for approximately $0.73.

How much money does MariMed make?

MariMed has a market capitalization of $243.20 million.

How many employees does MariMed have?

MariMed employs 207 workers across the globe.

What is MariMed's official website?

The official website for MariMed is marimedadvisors.com.

Where are MariMed's headquarters?

MariMed is headquartered at 11 ROYAL ROAD, BROOKLINE MA, 02445.

How can I contact MariMed?

MariMed's mailing address is 11 ROYAL ROAD, BROOKLINE MA, 02445. The company can be reached via phone at (617) 795-5140.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.